Evidence map›Paper›PMID 32231336›Full record

ArticleNature biotechnology2020

Combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted sequencing.

Joseph M Replogle, Thomas M Norman, Albert Xu, Jeffrey A Hussmann, Jin Chen, J Zachery Cogan, Elliott J Meer, Jessica M Terry, Daniel P Riordan, Niranjan Srinivas and 7 more

Open access · greenAbstract read
In one paragraph

Article in Nature biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 286 papers.

0numbers the graph read from it
0cells of the map it votes in
286citing papers in PubMed
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

286 citing papers in PubMed, 467 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

226 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Joseph M ReplogleMedical Scientist Training Program, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1832-919X
Thomas M NormanDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Albert XuMedical Scientist Training Program, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5938-561X
Jeffrey A HussmannDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7778-9893
Jin ChenDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
J Zachery CoganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Elliott J Meer10x Genomics Inc., Pleasanton, CA, USA.
Jessica M Terry10x Genomics Inc., Pleasanton, CA, USA.
Daniel P Riordan10x Genomics Inc., Pleasanton, CA, USA.
Niranjan Srinivas10x Genomics Inc., Pleasanton, CA, USA.
Ian T Fiddes10x Genomics Inc., Pleasanton, CA, USA.
Joseph G Arthur10x Genomics Inc., Pleasanton, CA, USA.
Luigi J Alvarado10x Genomics Inc., Pleasanton, CA, USA.ORCID http://orcid.org/0000-0002-7448-5384
Katherine A Pfeiffer10x Genomics Inc., Pleasanton, CA, USA.
Tarjei S Mikkelsen10x Genomics Inc., Pleasanton, CA, USA.ORCID http://orcid.org/0000-0002-8133-3135
Jonathan S WeissmanDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. jonathan.weissman@ucsf.edu.ORCID http://orcid.org/0000-0003-2445-670X
Britt AdamsonLewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA. badamson@princeton.edu.ORCID http://orcid.org/0000-0002-9451-5819
10X Genomics (United States) · USQB3 · USPrinceton University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human DiseaseRM1HG009490 · NHGRI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI Brittany S. Adamson, Martin Joseph Ankrah Aryee · 2017 to 2026
$22.7M
PROJECT 3P50GM102706 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI CATE, JAMIE H · 2012 to 2016
$9.5M
Bay Area Cancer Target Discovery and Development NetworkU01CA168370 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCORMICK, FRANK PATRICK, MCMANUS, MICHAEL T · 2012 to 2016
$3.9M
Harnessing CRISPR for Targeted and Inducible Epigenomic ReprogrammingR01DA036858 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A, QI, LEI STANLEY · 2013 to 2017
$2.9M
Defining the regulatory roles of alternative ribosome initiation and novel peptidesR00GM134154 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI CHEN, JIN · 2021 to 2022
$416k
Defining the regulatory roles of alternative ribosome initiation and novel peptidesK99GM134154 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, JIN · 2019 to 2020
$150k
The role of TMA7 in mitochondrial dysfunctionF31NS115380 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI REPLOGLE, JOSEPH · 2019 to 2020
$75k
Howard Hughes Medical InstituteNCI NIH HHS U01 CA168370NHGRI NIH HHS RM1 HG009490NIDA NIH HHS R01 DA036858NIGMS NIH HHS K99 GM134154NIGMS NIH HHS P50 GM102706NIGMS NIH HHS R00 GM134154NIGMS NIH HHS T32 GM007618NINDS NIH HHS F31 NS115380
6 · The paper itself

Abstract

Single-cell CRISPR screens enable the exploration of mammalian gene function and genetic regulatory networks. However, use of this technology has been limited by reliance on indirect indexing of single-guide RNAs (sgRNAs). Here we present direct-capture Perturb-seq, a versatile screening approach in which expressed sgRNAs are sequenced alongside single-cell transcriptomes. Direct-capture Perturb-seq enables detection of multiple distinct sgRNA sequences from individual cells and thus allows pooled single-cell CRISPR screens to be easily paired with combinatorial perturbation libraries that contain dual-guide expression vectors. We demonstrate the utility of this approach for high-throughput investigations of genetic interactions and, leveraging this ability, dissect epistatic interactions between cholesterol biogenesis and DNA repair. Using direct capture Perturb-seq, we also show that targeting individual genes with multiple sgRNAs per cell improves efficacy of CRISPR interference and activation, facilitating the use of compact, highly active CRISPR libraries for single-cell screens. Last, we show that hybridization-based target enrichment permits sensitive, specific sequencing of informative transcripts from single-cell RNA-seq experiments.

Indexed as

CRISPR-Cas SystemsGene Expression RegulationGene TargetingHEK293 CellsHigh-Throughput Nucleotide SequencingHumansNucleic Acid Amplification TechniquesRNA, Guide, CRISPR-Cas SystemsSingle-Cell AnalysisTranscriptomeRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID32231336
PMCPMC7416462
OpenAlexW3013900499

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.